Phaseline

Companies › Adagene

Adagene: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ADG126
anti-CTLA-4 monoclonal antibody
CTLA4Phase 1Advanced/Metastatic Solid Tumors; Locally Advanced Colorectal CancerJun 2027
ADG206
activatable anti-CD137 monoclonal antibody (IgG1 co-stimulatory agonist)
CD137Phase 1Advanced/Metastatic Solid Tumors–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05614258ADG206Phase 1Advanced/Metastatic Solid TumorsOncologyJun 2025
NCT05405595ADG126Phase 1Advanced/Metastatic Solid TumorsOncologyJun 2027
NCT06846268ADG126Phase 2Locally Advanced Colorectal CancerOncologyDec 2027

From the company's SEC filings

Cash and short-term investments of $75m on 2025-12-31; operating cash outflow about $16m a year; runway about 57 months at that burn, to Sep 2030; 1 of 1 coming phase 2-3 readouts fall inside that runway

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CTLA4 (1) CD137 (1)

Companies with the same targets

AstraZeneca Innovent Biopharmaceutical Technology (Hangzhou) Sichuan Baili Pharmaceutical Summit Therapeutics Revolution Medicines OncoC4 Bristol-Myers Squibb Akeso InxMed (Shanghai) Agenus

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.